DOTATATE
A somatostatin receptor targeting peptide (octreotate derivative) used as the targeting component in peptide receptor radionuclide therapy (PRRT), including 177Lu-DOTATATE for neuroendocrine tumors.
Tag
Oncology
Pages related to Oncology.
Hormone Therapy May Change a Tumor's Address
A first-in-human NTSR1 imaging study points to a stranger future for radiopharmaceutical oncology: after hormone therapy, some prostate tumors may stop showing one familiar address and start showing another.
A Tumor Used to Be a Place. Now It Might Be an Address.
A small DOTATATE PRRT pilot study in progressive meningioma points to a larger cancer idea: some tumors may be treatable not because of where they started, but because they display an address a radioactive peptide can find.
Peptide-drug conjugates are trying to turn cancer receptors into delivery doors
A cluster of new preclinical peptide-drug conjugate studies points to a subtle shift in oncology: using familiar cancer receptors less as signaling switches and more as delivery portals for toxic payloads.
Japan’s real-world 177Lu‑DOTATATE cohort gives PRRT a scale check
A nationwide multicenter retrospective study from Japan (422 patients, 33 institutions) reports real‑world outcomes for 177Lu‑DOTATATE PRRT in advanced neuroendocrine neoplasms. Response and progression-free survival look broadly consistent with PRRT’s established role, with useful predictor breakdowns.